200 related articles for article (PubMed ID: 28557009)
1. Drug concentration and antidrug antibodies in patients with psoriasis treated with adalimumab or etanercept.
Gyldenløve M; Zachariae C; Jensen P; Griehsel H; Ståhle M; Skov L
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e518-e519. PubMed ID: 28557009
[No Abstract] [Full Text] [Related]
2. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
[TBL] [Abstract][Full Text] [Related]
3. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis.
Kui R; Gál B; Gaál M; Kiss M; Kemény L; Gyulai R
J Dermatol; 2016 Sep; 43(9):1018-23. PubMed ID: 26892625
[TBL] [Abstract][Full Text] [Related]
4. Determination of adalimumab and etanercept trough levels and drug antibodies in long-term psoriasis treatment: a single-centre cohort study.
Manriquez J; Alsina-Gibert M
Clin Exp Dermatol; 2017 Jan; 42(1):14-20. PubMed ID: 27943384
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Antidrug Antibodies in Rheumatoid Arthritis Patients From Argentina Treated With Adalimumab, Etanercept, or Infliximab in a Real-World Setting.
Maid PJ; Xavier R; Real RM; Pedersen R; Shen Q; Marshall L; Solano G; Borlenghi CE; Hidalgo RP
J Clin Rheumatol; 2018 Jun; 24(4):177-182. PubMed ID: 29232322
[TBL] [Abstract][Full Text] [Related]
6. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis.
Mostafa NM; Nader AM; Noertersheuser P; Okun M; Awni WM
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):490-497. PubMed ID: 27545848
[TBL] [Abstract][Full Text] [Related]
7. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab.
Bissonnette R; Maari C; Barber K; Lynde CW; Vender R
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1576-81. PubMed ID: 25600828
[TBL] [Abstract][Full Text] [Related]
8. Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin.
D'Amico F; Trovato C; Skarmoutsou E; Rossi GA; Granata M; Longo V; Gangemi P; Pettinato M; Mazzarino MC
J Dermatol Sci; 2015 Oct; 80(1):38-44. PubMed ID: 26276441
[TBL] [Abstract][Full Text] [Related]
9. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
Bandrés Ciga S; Salvatierra J; López-Sidro M; García-Sánchez A; Durán R; Vives F; Raya-Álvarez E
J Clin Rheumatol; 2015 Apr; 21(3):115-9. PubMed ID: 25807089
[TBL] [Abstract][Full Text] [Related]
10. Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence.
Lombardi G; Perego S; Sansoni V; Diani M; Banfi G; Altomare G
BMJ Open; 2016 Dec; 6(12):e011941. PubMed ID: 27940624
[TBL] [Abstract][Full Text] [Related]
11. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.
Mahil SK; Arkir Z; Richards G; Lewis CM; Barker JN; Smith CH
Br J Dermatol; 2013 Aug; 169(2):306-13. PubMed ID: 23550925
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
Papp KA; Yang M; Sundaram M; Jarvis J; Betts KA; Bao Y; Signorovitch JE
Value Health; 2018 Jan; 21(1):1-8. PubMed ID: 29304933
[TBL] [Abstract][Full Text] [Related]
13. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
[TBL] [Abstract][Full Text] [Related]
14. [Anti-TNF biosimilars in psoriasis treatment].
Viguier M;
Ann Dermatol Venereol; 2019; 146(6-7):492-496. PubMed ID: 31239173
[No Abstract] [Full Text] [Related]
15. Importance of immunogenicity testing for cost-effective management of psoriasis patients treated with adalimumab.
Mota F; Neves E; Oliveira JC; Selores M; Torres T
Acta Dermatovenerol Alp Pannonica Adriat; 2017 Jun; 26(2):33-35. PubMed ID: 28632883
[TBL] [Abstract][Full Text] [Related]
16. Effect of Adalimumab on Gene Expression Profiles of Psoriatic Skin and Blood.
Chow M; Lai K; Ahn R; Gupta R; Arron S; Liao W
J Drugs Dermatol; 2016 Aug; 15(8):988-94. PubMed ID: 27538000
[TBL] [Abstract][Full Text] [Related]
17. Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria.
Richter L; Vujic I; Sesti A; Monshi B; Sanlorenzo M; Posch C; Rappersberger K
J Dtsch Dermatol Ges; 2017 Mar; 15(3):309-317. PubMed ID: 28240404
[TBL] [Abstract][Full Text] [Related]
18. Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value.
Elberdín L; Outeda M; Salvador P; Paradela S; Fernández-Torres RM; Iglesias R; Fonseca E; Martín I
Int J Clin Pharm; 2016 Oct; 38(5):1142-8. PubMed ID: 27436193
[TBL] [Abstract][Full Text] [Related]
19. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
[TBL] [Abstract][Full Text] [Related]
20. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up.
Menting SP; van Lümig PP; de Vries AC; van den Reek JM; van der Kleij D; de Jong EM; Spuls PI; Lecluse LL
JAMA Dermatol; 2014 Feb; 150(2):130-6. PubMed ID: 24352354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
